Comparison of Daiwa Brain Health (Hokkaido Scallop Oil Plasmalogen) and Prevagen (Apoaequorin) on Cognitive Function: An In-Office Pilot Study.

Objective: Daiwa Brain Health, which contains Hokkaido scallop oil plasmalogen, was compared with Prevagen, the market leader in the category of cognitive function improvement.

Methods: Thirty people with subjective cognitive decline or its premorbidities were divided into 2 groups of 15 people each, and each group was given either Daiwa Brain Health or Prevagen for 90 days. The Abbreviated Mental Test Score (AMTS) and Standardized Mini-Mental State Examination (SMMSE) were conducted before treatment and after 90 days of treatment to evaluate cognitive function.

Results: Participants who took Daiwa Brain Health showed statistically significant improvement in AMTS and SMMSE scores between baseline and 90 days of treatment, while participants who took Prevagen showed no statistically significant improvement in AMTS or SMMSE scores between baseline and after 90 days of treatment. The AMTS and SMMSE scores indicated higher cognitive function at 90 days after treatment for the participants who took Daiwa Brain Health compared with those who took Prevagen, and those differences were statistically significant.

Conclusion: Daiwa Brain Health is more effective than Prevagen at improving cognitive function.